Axon Enterprise, Inc. (NASDAQ:AXON) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Axon Enterprise, Inc. (NASDAQ:AXON) have been assigned a consensus recommendation of “Moderate Buy” from the fourteen analysts that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $365.38.

A number of brokerages recently issued reports on AXON. Northland Securities upped their price objective on shares of Axon Enterprise from $330.00 to $365.00 and gave the stock an “outperform” rating in a report on Thursday, August 8th. Barclays upped their price target on Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Jefferies Financial Group began coverage on Axon Enterprise in a research note on Wednesday, July 17th. They issued a “buy” rating and a $385.00 price objective on the stock. Craig Hallum lifted their price target on shares of Axon Enterprise from $370.00 to $376.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Finally, JMP Securities upped their price objective on shares of Axon Enterprise from $375.00 to $430.00 and gave the stock an “outperform” rating in a report on Thursday, September 12th.

Axon Enterprise Stock Performance

Shares of AXON stock opened at $393.29 on Friday. Axon Enterprise has a fifty-two week low of $189.12 and a fifty-two week high of $393.58. The stock’s 50-day moving average is $348.04 and its two-hundred day moving average is $317.22. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52. The firm has a market cap of $29.72 billion, a P/E ratio of 115.00, a PEG ratio of 10.34 and a beta of 0.94.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.18. The firm had revenue of $504.00 million for the quarter, compared to analyst estimates of $478.35 million. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The company’s revenue for the quarter was up 34.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.80 earnings per share. Analysts predict that Axon Enterprise will post 1.79 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Axon Enterprise news, Director Michael Garnreiter sold 1,000 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $380.99, for a total value of $380,990.00. Following the completion of the transaction, the director now owns 27,259 shares of the company’s stock, valued at approximately $10,385,406.41. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Axon Enterprise news, Director Michael Garnreiter sold 1,000 shares of Axon Enterprise stock in a transaction on Monday, September 16th. The shares were sold at an average price of $380.99, for a total transaction of $380,990.00. Following the sale, the director now owns 27,259 shares in the company, valued at $10,385,406.41. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, President Joshua Isner sold 25,811 shares of the stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $359.84, for a total transaction of $9,287,830.24. Following the completion of the transaction, the president now owns 228,166 shares of the company’s stock, valued at approximately $82,103,253.44. The disclosure for this sale can be found here. Insiders have sold a total of 317,981 shares of company stock valued at $115,662,734 over the last three months. 6.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Axon Enterprise

Institutional investors have recently added to or reduced their stakes in the stock. ICA Group Wealth Management LLC acquired a new stake in shares of Axon Enterprise in the 4th quarter valued at $26,000. Blue Trust Inc. boosted its position in Axon Enterprise by 987.5% in the second quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 79 shares in the last quarter. Trivant Custom Portfolio Group LLC bought a new stake in Axon Enterprise during the first quarter worth about $31,000. First PREMIER Bank acquired a new stake in shares of Axon Enterprise during the first quarter worth approximately $33,000. Finally, Rise Advisors LLC raised its stake in shares of Axon Enterprise by 49.0% in the first quarter. Rise Advisors LLC now owns 143 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 47 shares during the last quarter. 79.08% of the stock is owned by institutional investors and hedge funds.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.